| Identification | Back Directory | [Name]
(R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol | [CAS]
2408840-26-4 | [Synonyms]
LY-3484356
Imlunestrant
3-c]quinolin-2-ol
(R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-chromeno[4
(R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol
5H-[1]Benzopyrano[4,3-c]quinolin-2-ol, 5-[4-[2-[3-(fluoromethyl)-1-azetidinyl]ethoxy]phenyl]-8-(trifluoromethyl)-, (5R)- | [Molecular Formula]
C29H24F4N2O3 | [MOL File]
2408840-26-4.mol | [Molecular Weight]
524.51 |
| Chemical Properties | Back Directory | [Boiling point ]
682.9±55.0 °C(Predicted) | [density ]
1.360±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.57±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC)[1][2]. | [References]
[1] Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.
[2] Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812. |
|
|